FDA Approves UroGen's ZUSDURI for Recurrent Low-Grade Bladder Cancer
TL;DR Summary
UroGen Pharma's ZUSDURI, a new intravesical mitomycin formulation using sustained-release technology, has been approved by the FDA for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, offering a non-surgical alternative to TURBT with promising trial results showing high response rates.
- U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) Business Wire
- US FDA approves UroGen's bladder cancer drug Reuters
- FDA okays UroGen's bladder cancer treatment after narrow ODAC rebuff FirstWord Pharma
- FDA Approves Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC CancerNetwork
- Non-Surgical Option Approved for Recurrent Low-Grade Bladder Cancer MedPage Today
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
9 min
vs 10 min read
Condensed
98%
1,870 → 40 words
Want the full story? Read the original article
Read on Business Wire